Clozapine inhibits isolated N-methyl-D-aspartate receptors expressed in xenopus oocytes in a subunit specific manner

Neuroscience Letters

Volumn 346, Issue 3, 2003, Pages 125-128

  Levine, John B ^a,b   Martin, Gilles ^a   Wilson, Andrew ^a   Treistman, Steven N ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CAMBRIDGE HOSPITAL   (United States)

Author keywords

Clozapine; Electrophysiology; Glutamate; Neuropharmacology; Oocytes; Schizophrenia

Indexed keywords

CLOZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR SUBUNIT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; VOLTAGE CLAMP; XENOPUS;

EID: 0038645198     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00523-8     Document Type: Article

References (23)

1. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., Krystal J.H. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiatry. 57:2000;270-276.
2. Anantharam V., Panchal R.G., Wilson A., Kolchine V.V., Treistman S.N., Bayley H. Combinatorial RNA splicing alters the surface charge on the NMDA receptor. FEBS Lett. 305:1992;27-30.
3. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 283:1997;226-234.
4. Arvanov V.L., Wang R.Y. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J. Pharmacol. Exp. Ther. 289:1999;1000-1006.
5. Fletcher E.J., MacDonald J.F. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur. J. Pharmacol. 235:1993;291-295.
6. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 158:2001;1367-1377.
7. Hayashi T., Su T.P., Kagaya A., Nishida A., Shimizu M., Yamawaki S. Neuroleptics with differential affinities at dopamine D2 receptors and sigma receptors affect differently the N-methyl-D-aspartate-induced increase in intracellular calcium concentration: involvement of protein kinase. Synapse. 31:1999;20-28.
8. Ilyin V.I., Whittemore E.R., Guastella J., Weber E., Woodward R.M. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol. Pharmacol. 50:1996;1541-1550.
9. Jardemark K.E., Liang X., Arvanov V., Wang R.Y. Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate. Neuroscience. 100:2000;1-9.
10. Laurie D.J., Bartke I., Schoepfer R., Naujoks K., Seeburg P.H. Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. Brain Res. Mol. Brain Res. 51:1997;23-32.
11. Leonard A.S., Hell J.W. Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. J. Biol. Chem. 272:1997;12107-12115.
12. Leveque J.C., Macias W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., Li X.M., Coyle J.T., Huganir R.L., Heckers S., Konradi C. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci. 20:2000;4011-4020.
13. Lynch D.R., Gallagher M.J. Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors. J. Pharmacol. Exp. Ther. 279:1996;154-161.
14. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry. 42:1997;664-668.
15. McCoy L., Richfield E.K. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci. Lett. 213:1996;137-141.
16. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
17. Mullikin-Kilpatrick D., Treistman S.N. Inhibition of dihydropyridine-sensitive Ca++ channels by ethanol in undifferentiated and nerve growth factor-treated PC12 cells: interaction with the inactivated state. J. Pharmacol. Exp. Ther. 272:1995;489-497.
18. Rossi P., Sola E., Taglietti V., Borchardt T., Steigerwald F., Utvik J.K., Ottersen O.P., Kohr G., D'Angelo E. NMDA receptor 2 (NR2) C-terminal control of NR open probability regulates synaptic transmission and plasticity at a cerebellar synapse. J. Neurosci. 22:2002;9687-9697.
19. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
20. Shim S.S., Grant E.R., Singh S., Gallagher M.J., Lynch D.R. Actions of butyrophenones and other antipsychotic agents at NMDA receptors: relationship with clinical effects and structural considerations. Neurochem. Int. 34:1999;167-175.
21. Vissel B., Krupp J.J., Heinemann S.F., Westbrook G.L. Intracellular domains of NR2 alter calcium-dependent inactivation of N-methyl-D-aspartate receptors. Mol. Pharmacol. 61:2002;595-605.
22. Weber W.M. Endogenous ion channels in oocytes of Xenopus laevis: recent developments. J. Membr. Biol. 170:1999;1-12.
23. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry. 43:1986;114-124.